Rezafungin Noninferior To Caspofungin For Treatment Of Candidemia, Invasive Candidiasis, Trial Finds

Infectious Disease Advisor (1/9, Barowski) reports, “Rezafungin is noninferior to caspofungin for the treatment of candidemia and invasive candidiasis, according to” a “double-blinded, double-dummy, randomized phase 3 trial.” The results were published in...